RxDoctor Payments Data

Kathleen Stefek

Family · Asbury Park, NJNPI 1942480959

Payments from drug & device makers

$845in general payments, 2019–2025

Across 34 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$255
  • Novo Nordisk$210
  • Exact Sciences$133
  • Boehringer Ingelheim$62
  • Abbott$42
  • Amgen$33
  • plus $111 from 5 others

What the payments were for

  • Food & beverage$845100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$845 in reported general payments places this provider in the 70th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,115
Medicare patients
20
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol50$39,041
OzempicSemaglutide34$31,775
JanuviaSitagliptin Phosphate29$26,962
JardianceEmpagliflozin18$18,788
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$18,132
PremarinEstrogens, Conjugated16$12,601
EliquisApixaban20$11,664
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,021
Combivent RespimatIpratropium/Albuterol Sulfate15$7,904
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$5,466
Breo ElliptaFluticasone/Vilanterol11$5,359
Humalog Kwikpen U-100Insulin Lispro23$4,225
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$3,500
Albuterol Sulfate HfaAlbuterol Sulfate99$2,232
Azelastine Hcl43$1,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$210$31,77534 claims
Boehringer IngelheimJardiance, Combivent Respimat$62$26,69233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,692 family providers in New Jersey.

Other family in Asbury Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →